-

03:10:51 PM

CRBP Stock News

CRBP - Corbus Pharmaceuticals Holdings Inc

09/26/22 8:05 AM

Nasdaq : CRBP

management

Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors."Anne is a dynamic leader with a proven track record of

RHEA-AI

neutral

09/22/22 8:00 AM

Nasdaq : CRBP

clinical trial

Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference

CRB-913 is a novel oral cannabinoid type 1 receptor (CB1) inverse agonist with potent pre-clinical anti-obesity activity CRB-913 markedly enhances pre-clinical efficacy of liraglutide, semaglutide, and tirzepatide CB1 inverse agonism is a clinically validated therapeutic approach to treating

RHEA-AI

neutral

09/12/22 7:00 AM

Nasdaq : CRBP

conferences

Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference. The

RHEA-AI

neutral

08/09/22 8:00 AM

Nasdaq : CRBP

earnings

Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on track for mid-2023 Expanding immuno-oncology pipeline through strategic transactions remains key priority Cash and investments on

RHEA-AI

neutral

05/11/22 8:00 AM

Nasdaq : CRBP

clinical trial

Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference

CRB-601 is a highly potent and selective anti -?v?8 integrin monoclonal antibody designed to block the activation of TGF b in the local tumor microenvironment Additional non-clinical data demonstrates combination benefit across a diverse range of syngeneic models with differential sensitivity to

RHEA-AI

neutral

05/10/22 8:00 AM

Nasdaq : CRBP

earnings

Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on-track for the first half of 2023 Expanding immuno-oncology pipeline through strategic transactions remains key priority Cash and

RHEA-AI

neutral

04/08/22 1:05 PM

Nasdaq : CRBP

clinical trial

Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB-601 are being presented in a poster at the American Association for Cancer Research (AACR)

RHEA-AI

neutral

03/11/22 8:05 AM

Nasdaq : CRBP

conferences

Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32 nd Annual

RHEA-AI

neutral

03/08/22 8:05 AM

Nasdaq : CRBP

earnings

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the fourth quarter and year-end of 2021.Key Corporate and Program

RHEA-AI

neutral

12/07/21 8:05 AM

Nasdaq : CRBP

management

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will

RHEA-AI

neutral

CRBP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.corbuspharma.com
CeoYuval Cohen
Security nameCorbus Pharmaceuticals Holdings Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees76
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address500 River Ridge Drive
StateMassachusetts
CityNorwood
Zip02062
CountryUS
Phone16179630103

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.